Divergent expression of MUC5AC, MUC6, MUC2, CD10, and CDX-2 in dysplasia and intramucosal adenocarcinomas with intestinal and foveolar morphology: Is this evidence of distinct gastric and intestinal pathways to carcinogenesis in barrett esophagus?

American Journal of Surgical Pathology

Volumn 36, Issue 3, 2012, Pages 331-342

  Khor, Tze Sheng ^a,d   Alfaro, Eduardo E ^a,f   Ooi, Esther M M ^a,e   Li, Yuan ^a,g   Srivastava, Amitabh ^b,c   Fujita, Hiroshi ^a,h   Do Park, Youn ⁱ   Kumarasinghe, Marian Priyanthi ^d   Lauwers, Gregory Yves ^a,c  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d Path West Laboratory Medicine   (Australia)

^e UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^f UNIVERSIDAD DE COSTA RICA   (Costa Rica)

^g PEKING UNION MEDICAL COLLEGE HOSPITAL   (China)

^h KAGOSHIMA UNIVERSITY HOSPITAL   (Japan)

ⁱ Pusan National University School of Medicine   (South Korea)

Author keywords

adenomatous dysplasia; Barrett esophagus; CDX 2; foveolar dysplasia; hybrid dysplasia; immunophenotype; intramucosal adenocarcinoma; mucin core peptide expression

Indexed keywords

CDX2 PROTEIN, HUMAN; HOMEODOMAIN PROTEIN; MEMBRANE METALLOENDOPEPTIDASE; MUC2 PROTEIN, HUMAN; MUC5AC PROTEIN, HUMAN; MUC6 PROTEIN, HUMAN; MUCIN 2; MUCIN 5AC; MUCIN 6; TUMOR MARKER;

ADENOCARCINOMA; ADENOMA; AGED; ARTICLE; BARRETT ESOPHAGUS; CELL TRANSFORMATION; CHEMISTRY; ESOPHAGOSCOPY; ESOPHAGUS; ESOPHAGUS TUMOR; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOLOGY; IMMUNOPHENOTYPING; MALE; METABOLISM; MIDDLE AGED; MUCOSA; PATHOLOGY; PHENOTYPE; PRECANCER; RETROSPECTIVE STUDY;

ADENOCARCINOMA; ADENOMA; AGED; AGED, 80 AND OVER; BARRETT ESOPHAGUS; CELL TRANSFORMATION, NEOPLASTIC; ESOPHAGEAL NEOPLASMS; ESOPHAGOSCOPY; ESOPHAGUS; FEMALE; HOMEODOMAIN PROTEINS; HUMANS; IMMUNOHISTOCHEMISTRY; IMMUNOPHENOTYPING; MALE; MIDDLE AGED; MUCIN 5AC; MUCIN-2; MUCIN-6; MUCOUS MEMBRANE; NEPRILYSIN; PHENOTYPE; PRECANCEROUS CONDITIONS; RETROSPECTIVE STUDIES; TUMOR MARKERS, BIOLOGICAL;

EID: 84862810298     PISSN: 01475185     EISSN: 15320979     Source Type: Journal    
DOI: 10.1097/PAS.0b013e31823d08d6     Document Type: Article

References (39)

1. Brown IS, Whiteman DC, Lauwers GY. Foveolar type dysplasia in Barrett esophagus. Mod Pathol. 2010;23:834-843.
2. Chaves P, Cardoso P, de Almeida JC, et al. Non-goblet cell population of Barrett's esophagus: an immunohistochemical demonstration of intestinal differentiation. Hum Pathol. 1999;30:1291-1295.
3. Chaves P, Crespo M, Ribeiro C, et al. Chromosomal analysis of Barrett's cells: demonstration of instability and detection of the metaplastic lineage involved. Mod Pathol. 2007;20:788-796.
4. Chaves P, Cruz C, Cardoso P, et al. Enterocytic columnar nongoblet cells of Barrett's esophagus: an immunohistochemical demonstration of association with malignant evolution. J Exp Clin Cancer Res. 2003;22:273-278.
5. Coad RA, Woodman AC, Warner PJ, et al. On the histogenesis of Barrett's oesophagus and its associated squamous islands: a threedimensional study of their morphological relationship with native oesophageal gland ducts. J Pathol. 2005;206:388-394.
6. Dent J. Barrett's esophagus: a historical perspective, an update on core practicalities and predictions on future evolutions of management. J Gastroenterol Hepatol. 2011;26(suppl 1):11-30.
7. Fock KM, Ang TL. Global epidemiology of Barrett's esophagus. Expert Rev Gastroenterol Hepatol. 2011;5:123-130.
8. Gatenby PA, Ramus JR, Caygill CP, et al. Relevance of the detection of intestinal metaplasia in non-dysplastic columnar-lined oesophagus. Scand J Gastroenterol. 2008;43:524-530.
9. Goldblum JR, Lauwers GY. Dysplasia arising in Barrett's esophagus: diagnostic pitfalls and natural history. Semin Diagn Pathol. 2002;19:12-19.
10. Hahn HP, Blount PL, Ayub K, et al. Intestinal differentiation in metaplastic, nongoblet columnar epithelium in the esophagus. Am J Surg Pathol. 2009;33:1006-1015.
11. Hayes S, Ahmed S, Clark P. Immunohistochemical assessment for Cdx2 expression in the Barrett metaplasia-dysplasia-adenocarcinoma sequence. J Clin Pathol. 2011;64:110-113.
12. Hull MJ, Mino-Kenudson M, Nishioka NS, et al. Endoscopic mucosal resection: an improved diagnostic procedure for early gastroesophageal epithelial neoplasms. Am J Surg Pathol. 2006;30:114-118.
13. Kelty CJ, Gough MD, Van Wyk Q, et al. Barrett's oesophagus: intestinal metaplasia is not essential for cancer risk. Scand J Gastroenterol. 2007;42:1271-1274.
14. Liu Q, Teh M, Ito K, et al. CDX2 expression is progressively decreased in human gastric intestinal metaplasia, dysplasia and cancer. Mod Pathol. 2007;20:1286-1297.
15. Liu W, Hahn H, Odze RD, et al. Metaplastic esophageal columnar epithelium without goblet cells shows DNA content abnormalities similar to goblet cell-containing epithelium. Am J Gastroenterol. 2009;104:816-824.
16. Mahajan D, Bennett AE, Liu X, et al. Grading of gastric foveolartype dysplasia in Barrett's esophagus. Mod Pathol. 2010;23:1-11.
17. Maru DM. Barrett's esophagus: diagnostic challenges and recent developments. Ann Diagn Pathol. 2009;13:212-221.
18. McIntire MG, Soucy G, Vaughan TL, et al. MUC2 is a highly specific marker of goblet cell metaplasia in the distal esophagus and gastroesophageal junction. Am J Surg Pathol. 2011;35:1007-1013.
19. Montgomery E, Bronner MP, Goldblum JR, et al. Reproducibility of the diagnosis of dysplasia in Barrett esophagus: a reaffirmation. Hum Pathol. 2001;32:368-378.
20. Morris CD, Armstrong GR, Bigley G, et al. Cyclooxygenase-2 expression in the Barrett's metaplasia-dysplasia-adenocarcinoma sequence. Am J Gastroenterol. 2001;96:990-996.
21. Murray L, Watson P, Johnston B, et al. Risk of adenocarcinoma in Barrett's oesophagus: population based study. BMJ. 2003;327:534-535.
22. Park do Y, Srivastava A, Kim GH, et al. Adenomatous and foveolar gastric dysplasia: distinct patterns of mucin expression and background intestinal metaplasia. Am J Surg Pathol. 2008;32:524-533.
23. Park do Y, Srivastava A, Kim GH, et al. CDX2 expression in the intestinal-type gastric epithelial neoplasia: frequency and significance. Mod Pathol. 2010;23:54-61.
24. Piazuelo MB, Haque S, Delgado A, et al. Phenotypic differences between esophageal and gastric intestinal metaplasia. Mod Pathol. 2004;17:62-74.
25. Reid BJ, Weinstein WM. Barrett's esophagus and adenocarcinoma. Annu Rev Med. 1987;38:477-492.
26. Reid BJ, Weinstein WM, Lewin KJ, et al. Endoscopic biopsy can detect high-grade dysplasia or early adenocarcinoma in Barrett's esophagus without grossly recognizable neoplastic lesions. Gastroenterology. 1988;94:81-90.
27. Riddell RH, Goldman H, Ransohoff DF, et al. Dysplasia in inflammatory bowel disease: standardized classification with provisional clinical applications. Hum Pathol. 1983;14:931-968.
28. Rucker-Schmidt RL, Sanchez CA, Blount PL, et al. Nonadenomatous dysplasia in barrett esophagus: a clinical, pathologic, and DNA content flow cytometric study. Am J Surg Pathol. 2009;33:886-893.
29. Sampliner RE. Practice guidelines on the diagnosis, surveillance, and therapy of Barrett's esophagus. The practice parameters committee of the American College of gastroenterology. Am J Gastroenterol. 1998;93:1028-1032.
30. Schmidt HG, Riddell RH, Walther B, et al. Dysplasia in Barrett's esophagus. J Cancer Res Clin Oncol. 1985;110:145-152.
31. Seno H, Oshima M, Taniguchi MA, et al. CDX2 expression in the stomach with intestinal metaplasia and intestinal-type cancer: prognostic implications. Int J Oncol. 2002;21:769-774.
32. Sharma P, McQuaid K, Dent J, et al. A critical review of the diagnosis and management of Barrett's esophagus: the AGA Chicago Workshop. Gastroenterology. 2004;127:310-330.
33. Srivastava A, Odze RD, Lauwers GY, et al. Morphologic features are useful in distinguishing Barrett esophagus from carditis with intestinal metaplasia. Am J Surg Pathol. 2007;31:1733-1741.
34. Szachnowicz S, Cecconello I, Ribeiro U, et al. Mucin pattern reflects the origin of the adenocarcinoma in Barrett's esophagus: a retrospective clinical and laboratorial study. World J Surg Oncol. 2009;7:27.
35. Takubo K, Aida J, Naomoto Y, et al. Cardiac rather than intestinaltype background in endoscopic resection specimens of minute Barrett adenocarcinoma. Hum Pathol. 2009;40:65-74.
36. Takubo K, Nixon JM, Jass JR. Ducts of esophageal glands proper and paneth cells in Barrett's esophagus: frequency in biopsy specimens. Pathology. 1995;27:315-317.
37. Takubo K, Vieth M, Aryal G, et al. Islands of squamous epithelium and their surrounding mucosa in columnar-lined esophagus: a pathognomonic feature of Barrett's esophagus? Hum Pathol. 2005;36:269-274.
38. Tsukashita S, Kushima R, Bamba M, et al. MUC gene expression and histogenesis of adenocarcinoma of the stomach. Int J Cancer. 2001;94:166-170.
39. Wang KK, Sampliner RE. Updated guidelines 2008 for the diagnosis, surveillance and therapy of Barrett's esophagus. Am J Gastroenterol. 2008;103:788-797.